Neupogen and Temodar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Neupogen and Temodar. Common interactions include spinal column injury among females and anaemia among males.

The phase IV clinical study analyzes what interactions people who take Neupogen and Temodar have. It is created by eHealthMe based on reports of 31 people who take Neupogen and Temodar from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

31 people who take Neupogen and Temodar together, and have interactions are studied.

What is Neupogen?

Neupogen has active ingredients of filgrastim. It is often used in agranulocytosis. eHealthMe is studying from 22,961 Neupogen users for its effectiveness, alternative drugs and more.

What is Temodar?

Temodar has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 6,130 Temodar users for its effectiveness, alternative drugs and more.

Number of Neupogen and Temodar reports submitted per year:

Common Neupogen and Temodar drug interactions by gender *:

female:

Spinal column injury
Spinal osteoarthritis
Stress urinary incontinence
Swelling
Toothache
Vaginal prolapse
Visual impairment
Bone pain
Ear haemorrhage
Haematochezia

male:

Anaemia
Dehydration
Death
Deep vein thrombosis
Diarrhoea
Disease progression
Peripheral swelling
Thrombocytopenia
Abdominal tenderness
Aplastic anaemia

Common Neupogen and Temodar drug interactions by age *:

0-1:

n/a

2-9:

Haemoglobin decreased
Mucosal inflammation
Drug ineffective
Pancytopenia
Platelet count decreased
Pyrexia
White blood cell count decreased

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Dehydration
Confusional state
Death
Decreased appetite
Deep vein thrombosis
Diarrhoea
Disease progression
Fatigue
Gastrointestinal motility disorder
Lung infection

50-59:

Chest pain
Constipation
Escherichia infection
Febrile neutropenia
Gastrointestinal haemorrhage
Musculoskeletal chest pain
Platelet count decreased
Staphylococcal infection
White blood cell count decreased
Haematemesis

60+:

Anaemia
Blood lactate dehydrogenase increased
Azotaemia
Back pain
Blood creatinine increased
Bone disorder
Bone fissure
Bronchitis
Bruxism
Cellulitis

Common conditions people have *:

Nausea (feeling of having an urge to vomit): 3 people, 9.68%
Tracheal Cancer (cancer of trachea): 2 people, 6.45%
Stress And Anxiety: 2 people, 6.45%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 2 people, 6.45%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 2 people, 6.45%
Musculoskeletal Chest Pain (pain in chest muscle or nerve or bones): 2 people, 6.45%
Multiple Myeloma (cancer of the plasma cells): 2 people, 6.45%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 6.45%
Constipation: 2 people, 6.45%
Chest Pain: 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Neupogen and Temodar?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Neupogen (22,961 reports)
Temodar (6,130 reports)